Introduction
Insulin-like growth factor-I (IGF-I) is a 7.6 kDa polypeptide growth factor that plays an important role in cartilage physiology. 1, 2 In vitro, IGF-I stimulates chondrocyte mitotic activity, increases proteoglycan and type-II collagen synthesis and inhibits chondrocyte-mediated matrix catabolism. 3 In vivo, intra-articular IGF-I has been reported to modulate the progression of articular cartilage degradation 4 and to enhance the repair of articular cartilage defects. 5 Obstacles to the development of IGF-I as a therapeutic agent for articular cartilage damage that occurs in trauma and osteoarthritis include its short intraarticular residence time and the intrinsic paucity of articular chondrocytes to serve as target cells.
Gene transfer technologies offer a means of delivering therapeutic proteins to the joint space. [6] [7] [8] [9] Recent studies have demonstrated that isolated articular chondrocytes can be genetically modified [10] [11] [12] [13] [14] to express potentially beneficial genes 10, 14 and transplanted on to articular carti- lage. 10, 12, 13 It remains unknown whether articular chondrocytes can be transfected with a synthetic DNA delivery system to express and to produce sufficient quantities of a growth factor to influence chondrocyte metabolic function. It is additionally unknown whether, if achieved, such modifications could lead to detectable structural changes in cartilage formation.
The present study tests the hypothesis that overexpression and secretion of human IGF-I by transplantable articular chondrocytes can stimulate articular chondrocyte mitotic and matrix synthetic activity and augment the formation of new tissue in an ex vivo model of chondrocyte transplantation.
Results
Genetically modified bovine articular chondrocytes produce and secrete human IGF-I Transcription of the human IGF-I cDNA was assessed by Northern analysis of total RNA isolated from chondrocytes transfected with pCMV␤Gal or pCMVhIGF-I. Hybridization with a DNA probe corresponding to the human IGF-I cDNA in the transgene revealed a transcript of the anticipated 1.3 kb size. This corresponds to the predicted size of the 760 bp human IGF-I sequence with a polyadenylate tail. This transcript was absent in RNA from pCMV␤Gal-transfected cells, indicating that it is transcribed from the transgene rather than the native IGF-I gene.
To determine whether the IGF-I transcript is translated and the gene product released, conditioned medium from transfected chondrocytes was analyzed by IGF-I radioimmunoassay. Conditioned medium from cells transfected with pCMV␤Gal did not contain detectable IGF-I (n = 4). Mean IGF-I production by chondrocytes transfected with pCMVhIGF-I was 83 ± 22 ng per 1 × 10 7 cells/24 h (n = 4). . As predicted by the amino-acid sequence identity between human and bovine IGF-I 15 and prior studies, 16, 17 human IGF-I is effective in stimulating bovine articular chondrocytes.
Human

Tissue formed by transplanted transfected chondrocytes fulfills morphological and immunohistochemical criteria for cartilage
When transplanted on to the articular surface of cartilage disks, chondrocytes transfected with pCMV␤Gal or pCMVhIGF-I formed a layer of new tissue that covered the host explant surface (Figure 2 ). This newly formed tissue contained homogeneously distributed round cells with rounded nuclei, a morphology typical for chondrocytes. No spindle-shaped nuclei suggestive of a fibrocartilage phenotype were detected. pCMV␤Gal-transfected cells demonstrated no lacunae or cell orientation ( Figure  2a ). In contrast, pCMVhIGF-I-transfected cells were oriented perpendicular to the surface and were frequently surrounded by lacunae (Figure 2b ). The cells and matrix of the new tissue were intimately attached to the underlying host explant cartilage. The matrix in which the chondrocytes were embedded was intensely positive for proteoglycans by safranin O staining (Figure 2a and b) . By immunohistochemistry, the matrix of the new tissue and of the underlying host cartilage was negative for type I collagen (Figure 2c or pCMVhIGF-I was 38.5 ± 5.2 m and 67.3 ± 8.6 m thick, respectively (P Ͻ 0.001, n = 11). New tissue formed by transplanted non-transfected chondrocytes that were incubated in the absence or presence of 20 ng/ml exogenous rhIGF-I was 50.2 ± 3.3 m and 76.7 ± 2.3 m thick, respectively (P = 0.003, n = 5). The mean number of chondrocytes in the new tissue over each 56 m site along the explant surface was 18.2 ± 2.0 and 24.7 ± 2.1 for chondrocytes transfected with pCMV␤Gal and pCMVhIGF-I, 
Figure 2 Histologic sections of composite cultures composed of articular cartilage explants and transplanted genetically modified articular chondrocytes. Cells were transfected with the lacZ expression plasmid vector pCMV␤Gal or the human IGF-I expression plasmid vector pCMVhIGF-I and transplanted on to the surface of cartilage disks pretreated with chondroitin ABC lyase. Representative cross-sections of composite cultures composed of transplanted, pCMV␤Gal-transfected (a, c, e; left side) or pCMVhIGF-I-transfected chondrocytes (b, d, f; right side) stained with safranin O (a, b), a monoclonal anti-type I collagen antibody (c, d) or a polyclonal anti-type II collagen antibody (e, f). Pictures were taken with the same photographic parameters, including light intensity.
Original magnification, ×200.
respectively (P Ͻ 0.001, n = 11). The cell-to-matrix ratio, defined as the number of cells per 1000 m 2 crosssectional area of new tissue, was 8.2 ± 1.4 for pCMV␤Gal-transfected chondrocytes and 6.8 ± 1.5 for pCMVhIGF-Itransfected chondrocytes (P = 0.96, n = 3). Thus, the greater volume of tissue produced by pCMVhIGF-Itransfected cells reflects a commensurate increase in both cell number and matrix volume.
Chondrocytes overexpressing human IGF-I stimulate the metabolism of composite cell/explant cultures
When transfected chondrocytes were transplanted on to live cartilage explant disks, [ To distinguish between the respective contribution to the total radiolabel incorporation by (1) the cartilage explant disk, and (2) the new tissue formed on the disks Gene Therapy by the transfected chondrocytes, live ( Figure 3 , conditions (C-E) and dead (conditions A, B) cartilage disks were used as host explants for transplanted, transfected chondrocytes. The contribution of the explant disk is given by the difference in isotope uptake between cultures composed of transfected cells on live disks (conditions C or D) and that of cultures composed of the same cells on dead disks (conditions A or B), respectively. The percent contribution of the explant disks is calculated by the formula 100 × (1 − a/b), where b is the isotope uptake by cultures composed of transfected cells on live disks and a is the isotope uptake by cultures composed of the same cells on dead disks.
ANOVA revealed significant differences among the five conditions, F(4,43) = 10.83, P Ͻ 0.001. In composite cultures composed of pCMV␤Gal-transfected chondrocytes on live disks (condition C), the [ 3 H]thymidine incorporation was 1.9-fold higher (9273 ± 5230 c.p.m., n = 10) 
Discussion
Articular cartilage lost due to trauma or osteoarthritis does not heal of its own accord and remains an unresolved problem in joint disease. 18 One of the major problems in promoting the repair of damaged articular cartilage is the difficult accessibility of the cartilage to therapeutic agents and the lack of chondrocytes that might respond to a repair stimulus. We tested the hypothesis that the overexpression of human IGF-I by transplantable chondrocytes augments the chondrogenic activity of these cells in an ex vivo model of chondrocyte transplantation. The data indicate that chondrocytes transfected by a lipid-based method with a human IGF-I expression plasmid vector secrete relevant amounts of biologically active recombinant IGF-I protein. The data further demonstrate that overexpression of human IGF-I increased cell proliferation, matrix synthesis and new tissue formation by these chondrocytes when transplanted on to the surface of articular cartilage explants. In addition, the data indicate that overexpression of human IGF-I by transplanted chondrocytes augmented the cellular activity of the chondrocytes residing within the host explant cartilage.
Lipid-based gene transfer methods have been shown to efficiently transfect articular chondrocytes with the reporter gene lacZ. 13 Growth factor production by chondrocytes genetically modified by nonviral methods has not, to our knowledge, been previously reported. The mean IGF-I production rate by the articular chondrocytes used in these studies was 83 ng/10 7 cells/24 h. This is comparable to the 92 ng IGF-I/10 7 cells/24 h reported for a transfected bovine mammary epithelial cell line selected for cells carrying the transgene, 19 but less than the 560 ng IGF-I/10 7 cells/24 h produced by keratinocytes following retroviral gene transfer and selection. 20 These differences may reflect different synthetic activities of the respective cell types, differences in the human IGF-I expression construct or the selection of modified cells.
The role of IGF-I in articular chondrocyte growth and matrix synthesis has been investigated in several studies 2, 14 and illustrated in the enhanced repair of articular cartilage defects by the application of fibrin composites containing insulin-like growth factor-I protein. 5 In the present studies, articular chondrocyte transfection with a human IGF-I expression plasmid vector stimulated the biosynthetic activity of chondrocytes as measured by enhanced [
H]thymidine and [
35 S]sulfate incorporation, indices of DNA and glycosaminoglycan synthesis, respectively. However, such measurements of biosynthetic activity may overestimate the value of these growth factor actions because some of the newly synthesized glycosaminoglycans may not be incorporated into functional matrix. 14, 21 Furthermore, increases in DNA synthesis may overestimate increases in cell numbers in short-term experiments. In the present studies, transfection of articular chondrocytes with a human IGF-I expression plasmid vector increased structural parameters of chondrogenic activity, including the formation of new tissue matrix, and increased the number of cells within the new tissue. This indicates that the newly synthesized glycosaminoglycans are, at least in part, incorporated into the new tissue structure, rather than simply being secreted into the culture medium, and that DNA synthesis reflects cell proliferation.
Although the augmentation by pCMVhIGF-I of the new tissue thickness (77%) was greater than that of new tissue cell number (39%), the cell-to-matrix ratio was not statistically different between these two groups (P = 0.96). This suggests that, during this phase of chondrogenesis, the overexpression of human IGF-I increases cell proliferation, but does not significantly increase synthesis per cell of matrix that is retained in the new tissue.
The new tissue formed by IGF-I-overexpressing cells was characterized as cartilage by the morphology of the chondrocytes and the composition of the matrix, including the presence of proteoglycan and type II collagen, and the absence of type I collagen. This is consistent with the short-term (4-5 day) period of monolayer culture 13 followed by three-dimensional culture in the composite model, conditions that avoid chondrocyte phenotypic drift. 22 Of interest was the observation that the new tissue formed by the transplanted chondrocytes was intimately integrated with the host explant articular cartilage surface. Before chondrocyte transplantation, proteoglycans at the explant surfaces were partially removed by treatment with chondroitin ABC lyase to promote cell attachment. 23 It is possible that this 'damage' to the articular surface due to exposure to degradative enzymes may have facilitated the formation of the interface between the new and old tissue.
The analysis of the two components (transplanted chondrocytes and host explant chondrocytes) of the composite cultures with respect to radiolabel incorporation indicates that IGF-I synthesized by the transplanted chondrocytes affected the mitotic activity of both the new tissue and the underlying explant cartilage. In composite cultures with transplanted pCMVhIGF-I-transfected chondrocytes, the increase in [ 3 H]thymidine occurred principally in the underlying host cartilage. In contrast, in composite cultures with pCMV␤Gal-transfected chondrocytes, [ 3 H]thymidine incorporation was approximately evenly distributed between transplanted and host chondrocytes.
Interestingly, when pCMVhIGF-I-transfected chondro-cytes were transplanted on to dead disks ( Figure 3 , condition B), incorporation of [ 3 H]thymidine was not significantly different than that by transplanted pCMV␤Gal-transfected chondrocytes on to dead disks ( Figure 3 , condition A). The mechanisms underlying these observations are unknown, but suggest that the condition of the host cartilage may influence the biosynthetic function of the transplanted cells.
The transplantation of chondrocytes transduced with an interleukin-1 receptor antagonist gene has been reported to protect cartilage from interleukin-1-induced extracellular matrix degeneration. 10 Our data support the concept that transplanted chondrocytes transfected with a growth factor gene are able to stimulate the biosynthetic activity of the host cartilage.
This technology has potential applications for promoting the repair of articular cartilage defects sustained as a result of trauma or osteoarthritis. In such an application, transfected transplanted chondrocytes could serve the dual role of providing a repair stimulus to the host tissue and an appropriate target cell population capable of chondrogenesis. Further studies will be required to determine the effect of chondrocytes overexpressing human IGF-I on articular cartilage in vivo.
Materials and methods
Expression constructs
The human IGF-I cDNA 24 from the pBShIGF-I plasmid containing the entire coding region was inserted as a 760 bp PstI fragment into pcDNA3.1/Zeo(+) (Invitrogen, Carlsbad, CA, USA) containing the human cytomegalovirus immediate-early (CMV-IE) promoter/enhancer and the bovine growth hormone polyadenylation signal. The expression vector was designated pCMVhIGF-I. The plasmid pCMVSport␤Gal (Gibco Life Technologies, Grand Island, NY, USA) containing the Escherichia coli (E. coli) ␤-galactosidase (lacZ) gene under the control of the CMV-IE promoter/enhancer was employed (termed pCMV␤Gal). Plasmids were subjected to endotoxin-free maxipreparation (Qiagen, Hilden, Germany).
Cell culture and transfection
Bovine articular chondrocytes were isolated as previously described. 1 Briefly, articular cartilage was obtained from radiocarpal joints of 1-to 2-week-old calves. Underlying vascularized cartilage was excluded. Cartilage was incubated in DMEM with 50 g/ml ascorbic acid, 100 U/ml penicillin G and 100 l/ml streptomycin (basal medium; all GIBCO Life Technologies) containing 0.09% collagenase (Worthington, Lakewood, NJ, USA) at 37°C in a humidified atmosphere with 10% CO 2 for 16 h. Isolated cells were placed in monolayer culture in basal medium containing 10% FBS (growth medium). Transfections were performed as previously described. 13 Briefly, 29 g plasmid DNA were complexed with 87 l FuGENE 6 (Roche, Indianapolis, IN, USA) in Opti-MEM (GIBCO Life Technologies) and transferred to subconfluent chondrocyte monolayers. Cells were treated with 4 U/ml bovine testicular hyaluronidase (Sigma, St Louis, MO, USA) 12 h before and during transfection.
RNA isolation and Northern analysis
Total cellular RNA was extracted 8 days after transfection (RNeasy; Qiagen), fractionated on 1% agarose gels and Gene Therapy transferred to nylon membranes (BioRad, Hercules, CA, USA). After cross-linking of the membranes and prehybridization, RNA was hybridized for 16 h at 42°C to a human IGF-I or a bovine GAPDH cDNA probe labeled with [ 32 P] dCTP using a random primer labeling kit (Stratagene, La Jolla, CA, USA). The final stringency of wash was 0.5 × SSPE, 0.5% SDS at 65°C.
Cartilage explant culture and cell transplantation Articular cartilage explant cultures were prepared from the radiocarpal joints of 1-to 2-week-old calves as 6.2 mm diameter cartilage disks and individually incubated in 96-well plates containing basal medium with 2% FBS. Transplantation of chondrocytes on to the cartilage disks (0.8 × 10 6 cells/disk) pretreated with 1 U/ml chondroitin ABC lyase (ICN, Irvine, CA, USA) in PBS for 1 h at 37°C was performed as previously described. 13 The cell/explant composites were cultured for 5 days under the designated conditions. Dead control cartilage disks were prepared by subjecting the tissue to eight freeze (−80°C)-thaw cycles.
IGF-I protein analysis
Bovine articular chondrocytes were transfected with either pCMV␤Gal or pCMVhIGF-I and cultured in growth medium. Two days later, cell layers were washed twice and the medium was replaced with serum-free MCDB-105 (Sigma). After 48 h, the conditioned medium was removed, centrifuged to remove cell debris and stored at −80°C. To determine IGF-I protein production, conditioned medium was subjected to acid-ethanol extraction of binding proteins and analyzed by radioimmunoassay (Nichols Institute, San Juan Capistrano, CA, USA) with a detection limit of 20 ng/ml. 17 For analysis of the effect of conditioned medium from pCMV␤Gal-or pCMVhIGF-Itransfected chondrocytes, separate monolayer cultures of non-transfected bovine articular chondrocytes in 96-well plates were incubated in 50% conditioned medium (1:1 conditioned medium/MCDB-105) or in graded concentrations of recombinant human IGF-I (rhIGF-I; Peprotech, Rocky Hills, NJ, USA) for 48 h. After 32 h, [ 3 H]thymidine (8 Ci/ml) and [ 
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